Eli Lilly unveiled final data from the MONARCH 3 study that helped the drug garner FDA approval in February 2018 for the treatment of some breast cancer patients.
The U.S. Food and Drug Administration on Tuesday allowed genetic testing company 23andMe to market directly to consumers its test that will help assess three mutations in a common type of breast cancer gene.
A European Medicines Agency panel recommended against approving Puma Biotechnology’s lead breast cancer drug, an outcome the U.S drugmaker signaled in January 2018.
Fast Company recently published The World’s 50 Most Innovative Companies 2018, topping off its edition of the top 350 most innovative companies. Here is a look at the life science companies that made the list.
Bothell, Washington-based Seattle Genetics announced it is buying Seattle-based Cascadian Therapeutics for about $614 million.
Puma Biotechnology Inc. said a European regulatory panel indicated it was unlikely to provide a positive opinion on the company’s breast cancer drug.
Pharma giant AstraZeneca has seen a fourfold increase in research productivity following a narrowing of disease focus and cuts in laboratory and staff over the past seven years, Reuters reported.
Novartis’ Kisqali (ribociclib) won U.S. Food and Drug Administration breakthrough therapy designation for treating some breast cancer patients.
Normal immune cells that live near milk ducts in healthy breast tissue may play a key role in helping early breast cancer cells leave the breast for other parts of the body, researchers say.
Odonate Therapeutics Inc. announced that it has initiated CONTESSA, a multinational, multicenter, randomized, Phase 3 study of tesetaxel in patients with locally advanced or metastatic breast cancer.